COPD activates bitter taste receptors, the target of asthma treatment

Published Date: 17 Mar 2023

Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...

Read Full News

Latest News

COPD in 2025: Year in Review

COPD in 2025: Year in Review

Characterizing COPD - Lung Cancer Patients, with Joseph Friedberg, MD Joseph Friedberg, MD, Kevin Kunzmann

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Todays Updates

Real-World Use of Clinical Biomarkers in the Updated Multiple Sclerosis Diagnostic Criteria Isabella Ciccone, MPH, Agne Straukiene, MD, Daniel Ontaneda, MD, PhD, Carrie Hersh, DO, MSc, FAAN

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

From the Field: Neurologist-Written Insights From 2025 NeurologyLive® Staff

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

Todays Updates

Real-World Use of Clinical Biomarkers in the Updated Multiple Sclerosis Diagnostic Criteria Isabella Ciccone, MPH, Agne Straukiene, MD, Daniel Ontaneda, MD, PhD, Carrie Hersh, DO, MSc, FAAN

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

From the Field: Neurologist-Written Insights From 2025 NeurologyLive® Staff

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

Latest News

COPD in 2025: Year in Review

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

News All Time

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Long-Term Data Support New Zopapogene Imadenovec Approval for RRP Victoria Johnson

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma Victoria Johnson

The therapy is currently approved in almost 50 countries under the name Trimbow.

FDA Approval Adds Tezepelumab to CRSwNP Treatment Landscape Victoria Johnson

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s Kevin Kunzmann

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

4 Trials That May Change Pulmonary Embolism, with Parth Rali, MD Parth Rali, MD

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers Victoria Johnson

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Opportunities to Define and Treat Indoor Air Quality, with Sarath Raju, MD, MPH Sarath Raju, MD, MPH

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

What Ails Lung Cancer Screening, with Douglas Wood, MD Douglas Wood, MD

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

Recommended News For You

Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer

Despite reports of hundreds of cancer cases, carcinogens have been discovered at nuclear missile sites in Montana.

Rising rates of head and neck cancers in England

Health researchers discuss Medicaid cancer screening trends, best practices

Testosterone recovery linked to overall survival in high-risk prostate cancer

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

Recommended Articles For You

Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy 

Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More  

Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results 

Exploring Dyscrasias: Uncovering the Causes and Treatments of Unusual Blood Disorders 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New BCMA-Directed Therapies Show Promise in Multiple Myeloma

2.

Research indicates that combining AI models enhances the ability to predict breast cancer risk.

3.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care

4.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

5.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

1.

Debunking Myths About Systemic Mastocytosis: Separating Fact from Fiction 

2.

Cardio-Oncology: Managing Heart Failure in Survivors of Cancer

3.

The Danger of Rectus Sheath Hematoma: A Hidden Risk of Abdominal Surgery

4.

A Visual Guide to Understanding Breast Cancer Staging

5.

An Overview Of Daunorubicin: What Is It Used For And How Does It Work?

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

2.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

3.

Navigating the Complexities of Ph Negative ALL - Part VI

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

5.

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot